Drug
Cobiprostone
Cobiprostone is a pharmaceutical drug with 3 clinical trials. Historical success rate of 33.3%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
2(67%)
Phase Distribution
Ph phase_2
3
100%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Terminated2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
Phase 2
Trials by Phase
Phase 23 (100.0%)
Trials by Status
completed133%
terminated267%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury
NCT00597818
terminatedphase_2
Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy
NCT02542215
terminatedphase_2
Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension
NCT00737594
Clinical Trials (3)
Showing 3 of 3 trials
NCT00597818Phase 2
Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury
NCT02542215Phase 2
Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy
NCT00737594Phase 2
Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3